DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

Information source: M.D. Anderson Cancer Center
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Lymphoma, T-Cell; Mycosis Fungoides; Hematologic Neoplasms

Intervention: Accutane (Drug); Interferon Alpha (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: M.D. Anderson Cancer Center

Summary

The purpose of this study is to determine the response rate of patients with T-cell malignancies to combination therapy using interferon-alpha (Roferon) and Isotretinoin (Accutane).

Clinical Details

Official title: Phase 2 Study of Interferon Alpha and Isotretinoin in Patients With T-Cell Malignancies

Study design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study

Detailed description: Retinoids have shown activity in T-cell malignancies in past studies (both isotretinoin and etretinate) with an overall response rate of about 60%. One third of those responses were complete responses. Interferon-alpha has proven efficacy in wide ranges of human malignancies including T-cell lymphomas as a single agent. A clinical trial was needed to evaluate the response rate of these two agents combined.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

- Histologic proof of incurable T-Cell malignancy and not eligible for existing higher

priority protocols.

- Patients should not have received chmoe, immuno, hormonal, or radiation therapy within

3 weeks of entry into this study and must have recovered from acute toxic effects of prior therapy.

- Life expectancy of at least 12 weeks and a ZUBROD status of

- Signed informed consent.

- Measurable or evaluable disease.

- >/= 18 years of age.

- No other current chemo, immuno, or radiotherapy allowed.

- Bilirubin

- Serum creatinine

- Serum triglyceride level

- Patients may not have serious intercurrent medical illness.

- Patients of childbearing potential must practice adequate contraception.

- Patients will eligible regardless of the extent of prior chemotherapy.

Locations and Contacts

M. D. Anderson Cancer Center, Houston, Texas 77030, United States
Additional Information

Official website for M. D. Anderson Cancer Center

Starting date: May 1990
Last updated: August 11, 2005

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012